Chest Medicine
Another study shows a single dose of an mRNA vaccine has maximal effects in those with past infection.
24 Jun, 2021 | 10:38h | UTCPrimary, Recall, and Decay Kinetics of SARS-CoV-2 Vaccine Antibody Responses – ACS Nano
Related: France recommends single dose of vaccine if previous Covid infection detected. AND [Preprint] More data showing a single-dose SARS-CoV-2 mRNA vaccine may be enough in individuals with previous COVID-19. AND Another study shows a single dose of mRNA vaccine may be enough for patients with previous Covid-19
Commentary on Twitter
Prior covid? Unless it's a severe case, one-dose mRNA vaccine adds considerable protection and nothing added by 2nd dose. This is now concordant w/ >20 studieshttps://t.co/8Qpuw193zk @acsnano pic.twitter.com/TJNbl8HPy9
— Eric Topol (@EricTopol) June 23, 2021
Effect of Vaccination on Household Transmission of SARS-CoV-2 in England – “the likelihood of household transmission was approximately 40 to 50% lower in households of index patients who had been vaccinated 21 days or more before testing positive than in households of unvaccinated index patients”.
24 Jun, 2021 | 09:52h | UTCRelated: Study in England showed one dose of COVID-19 vaccine can cut household transmission by up to half – This protection is on top of the reduced risk of a vaccinated person developing symptomatic infection, which is around 60 to 65% after the first dose AND Covid-19 vaccination prevents transmission from vaccinated to unvaccinated household members.
Report: SARS-CoV-2 variants and vaccines.
24 Jun, 2021 | 10:33h | UTCSARS-CoV-2 Variants and Vaccines – New England Journal of Medicine
Perspective | Delta variant triggers dangerous new phase in the pandemic.
24 Jun, 2021 | 10:43h | UTCDelta variant triggers dangerous new phase in the pandemic – Science
CDC: mRNA vaccines are likely linked to cases of myocarditis and pericarditis – 1,226 cases of myocarditis or pericarditis have been reported mostly in people under 30.
24 Jun, 2021 | 09:51h | UTCSee also: Experts: mRNA COVID-19 vaccines likely tied to heart inflammation – CIDRAP
Related: Case series: 7 cases of myocarditis following mRNA-based COVID-19 vaccination. AND Case series: clinical and cardiac magnetic resonance imaging findings of 4 cases of myocarditis following mRNA-based COVID-19 vaccination. AND Case series: symptomatic acute myocarditis in 7 adolescents following mRNA COVID-19 vaccination. AND CDC says heart inflammation cases were higher than expected in 16- to 24-year-olds after second Covid vaccine shot, but still rare. AND Israel reports link between rare cases of heart inflammation and COVID-19 vaccination in young men. AND CDC is investigating several reports that teenagers and young adults may have developed myocarditis after receiving mRNA vaccines. Most cases were mild, more often in males than females, more often following dose 2 than dose 1, and typically, within 4 days after vaccination.
[News release – not published yet] COVID-19 outpatient thrombosis prevention trial ends early – “Results suggest that not treating certain symptomatic but stable outpatients with anticoagulant or antiplatelet therapy may be the best course of action”.
23 Jun, 2021 | 10:32h | UTCCommentary: Antithrombotics No Help for Stable COVID-19 Outpatients: ACTIV-4b – TCTMD
Interactive Infographic | Interpreting a lateral flow SARS-CoV-2 antigen test – “This calculator demonstrates how interpreting a covid-19 lateral flow device (LFD) result varies according to the pre-test probability, and the sensitivity and specificity of the LFD used”.
23 Jun, 2021 | 10:29h | UTCInterpreting a lateral flow SARS-CoV-2 antigen test – The BMJ
Laboratory testing for suspected COVID-19 vaccine–induced (immune) thrombotic thrombocytopenia.
23 Jun, 2021 | 10:25h | UTC
Delta coronavirus variant: scientists brace for impact.
23 Jun, 2021 | 10:27h | UTCDelta coronavirus variant: scientists brace for impact – Nature
New Analysis reveals link between birthdays and COVID-19 spread during the height of the pandemic.
23 Jun, 2021 | 10:22h | UTCNews release: New Analysis reveals link between birthdays and COVID-19 spread during the height of the pandemic – Harvard Medical School
Original Study: Assessing the Association Between Social Gatherings and COVID-19 Risk Using Birthdays – JAMA Internal Medicine
Commentary on Twitter (thread – click for more)
The link between birthdays and Covid-19
Thread on our new study (w/ @CM_Whaley, Jon Cantor, Megan Pera) in @JAMAInternalMed
Using data on ~3M households, households in which a member had bday 2 wks prior were ~30% more likely to have a covid diagnosishttps://t.co/KHCvGAlvox
— Anupam Jena (@AnupamBJena) June 21, 2021
The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-analysis, GRADE Assessment, and International Consensus Approach.
23 Jun, 2021 | 10:23h | UTC
AHA Scientific Statement: Obstructive Sleep Apnea and Cardiovascular Disease.
23 Jun, 2021 | 10:16h | UTCNews Release: Sleep apnea worsens heart disease, yet often untreated – American Heart Association
[Preprint] Rapid displacement of SARS-CoV-2 variant B.1.1.7 (Alpha) by B.1.617.2 (Delta) and P.1 (Gamma) in the United States.
22 Jun, 2021 | 10:12h | UTCRapid displacement of SARS-CoV-2 variant B.1.1.7 by B.1.617.2 and P.1 in the United States – medRxiv
Commentary on Twitter
🆕💥💥Preprint
📌B.1.617.2 Delta and P.1 are growing faster than B.1.1.7 & B.1.617.2 is growing faster than P.1 in the US
📌B.1.617.2 will soon be the dominant variant in the US
📌B.1.617.2 is growing more rapidly in counties with lower vaccination rateshttps://t.co/6Rf3p5N4ed pic.twitter.com/sVzyQRXn12— Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 (@ABsteward) June 22, 2021
Ivermectin is the new hydroxychloroquine, take 2 – “Ivermectin shouldn’t be used to treat COVID-19 outside of the context of a well-designed clinical trial”.
22 Jun, 2021 | 10:08h | UTCIvermectin is the new hydroxychloroquine, take 2 – Science-Based Medicine
Related: [Preprint] Meta-analysis of RCT: Ivermectin for the treatment of COVID-19 – no effect on all-cause mortality, length of stay, or viral clearance AND M-A: Prophylaxis against Covid-19: 1 – no benefit from Hydroxychloroquine; 2 – as studies on ivermectin so far have been small, it remains very uncertain whether ivermectin reduces SARS-CoV-2 infection AND Therapeutics and COVID-19 | WHO guideline update advises Ivermectin should only be used to treat COVID-19 within clinical trials AND EMA advises against use of ivermectin for the prevention or treatment of COVID-19 outside randomized clinical trials AND FDA: Why you should not use Ivermectin to treat or prevent COVID-19 AND RCT: Ivermectin does not improve time to resolution of symptoms among adults with mild COVID-19 AND NIH Guideline Statement: “there are insufficient data to recommend either for or against the use of ivermectin for the treatment of COVID-19” AND Video (5min): Ivermectin for COVID-19 | A Doctor Explains
Perspective | COVID-19: The rise and rise of Delta.
22 Jun, 2021 | 10:10h | UTCCOVID-19: The rise and rise of Delta – Sciblogs
Case report: Multisystem inflammatory syndrome in an adult after SARS-CoV-2 infection.
22 Jun, 2021 | 10:04h | UTC
Increased transmissibility and global spread of SARS-CoV-2 variants of concern – “Estimated transmissibility increases of alpha 29% (95% CI: 24–33), beta 25% (95% CI: 20–30), gamma 38% (95% CI: 29–48) & delta 97% (95% CI: 76–117)”.
21 Jun, 2021 | 08:55h | UTC
Commentary on Twitter
NEW publication in Eurosurveillance
Increased transmissibility & global spread of #SARSCoV2 VOC & VOI
Estimated transmissibility increases of alpha 29% (95% CI: 24–33), beta 25% (95% CI: 20–30), gamma 38% (95% CI: 29–48) & delta 97% (95% CI: 76–117)
⬇️https://t.co/pmyfQMM78y pic.twitter.com/Xz3cOImRvc
— Maria Van Kerkhove (@mvankerkhove) June 17, 2021
National surveillance in England showed low risk of reinfection with Covid-19 – “There were 15,893 possible reinfections with SARS-CoV-2 identified up to 30 May 2021 in England throughout the pandemic, out of nearly 4 million people with confirmed infections. This is equivalent to around 0.4% cases becoming reinfected”.
21 Jun, 2021 | 08:56h | UTCNew national surveillance of possible COVID-19 reinfection, published by PHE – Public Health England
Related: Had COVID? You’ll probably make antibodies for a lifetime – Nature AND COVID-19 reinfection rate less than 1 percent for those with severe illness, study finds. AND Study shows low risk of SARS-CoV-2 reinfection 1 year after primary infection.
M-A: Azithromycin does not reduce the need for invasive mechanical ventilation or mortality in patients with Covid-19.
21 Jun, 2021 | 08:45h | UTC
Concerned about the latest AstraZeneca news? These 3 graphics help you make sense of the risk – “Two people in Australia have died from thrombosis with thrombocytopenia after 3.8 million doses of the AstraZeneca vaccine delivered”.
21 Jun, 2021 | 08:48h | UTC
Review: Advances in the diagnosis and treatment of primary ciliary dyskinesia.
21 Jun, 2021 | 08:27h | UTCAdvances in the Diagnosis and Treatment of Primary Ciliary Dyskinesia: A Review – JAMA Otolaryngology – Head & Neck Surgery (free for a limited period)
RCT: Routine use of prophylactic postoperative continuous positive airway pressure (CPAP) does not prevent pneumonia, re-intubation, and death after major abdominal surgery.
21 Jun, 2021 | 08:32h | UTCPostoperative continuous positive airway pressure to prevent pneumonia, re-intubation, and death after major abdominal surgery (PRISM): a multicentre, open-label, randomised, phase 3 trial – The Lancet Respiratory Medicine (link to abstract – $ for full-text)
Commentary on Twitter (thread – click for more)
Published today in @LancetRespirMed is the final report of @prismtrial, an international multi-centre phase-3 randomised trial of routine postoperative CPAP to prevent pneumonia, re-intubation & death after major abdominal surgery https://t.co/e09pSTi2sa @rupert_pearse @QMULWHRI
— Tom Abbott (@_tomabbott) June 19, 2021
Opinion | Causation or confounding: why controls are critical for characterizing long COVID – “Many of the self-reported symptoms, such as intermittent headaches or tiredness, are nonspecific and prevalent in the general population”.
18 Jun, 2021 | 08:29h | UTCCausation or confounding: why controls are critical for characterizing long COVID – Nature
Dr. Fauci says the risks from the Delta variant underscore the importance of vaccines.
18 Jun, 2021 | 08:31h | UTCDr. Fauci Says The Risks From The Delta Variant Underscore The Importance Of Vaccines – NPR
Cohort study: swallowing and voice outcomes in patients hospitalized with COVID-19.
18 Jun, 2021 | 08:24h | UTCRelated study: Characterization of dysphagia and laryngeal findings in COVID-19 patients treated in the ICU—An observational clinical study – PLOS One